Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pancreaticoduodenectomy | 41 | 2022 | 64 | 5.160 |
Why?
|
Pancreatic Neoplasms | 46 | 2023 | 339 | 4.240 |
Why?
|
Pancreatitis, Acute Necrotizing | 23 | 2022 | 24 | 3.690 |
Why?
|
Pancreatectomy | 36 | 2023 | 101 | 3.450 |
Why?
|
Carcinoma, Pancreatic Ductal | 20 | 2023 | 111 | 2.150 |
Why?
|
Postoperative Complications | 26 | 2023 | 1284 | 1.410 |
Why?
|
Laparoscopy | 13 | 2021 | 468 | 1.290 |
Why?
|
Pancreatic Ducts | 11 | 2020 | 30 | 1.280 |
Why?
|
Adenocarcinoma | 15 | 2022 | 337 | 1.270 |
Why?
|
Drainage | 15 | 2022 | 154 | 1.110 |
Why?
|
Retrospective Studies | 76 | 2023 | 6545 | 1.070 |
Why?
|
Pancreatic Fistula | 10 | 2021 | 18 | 1.050 |
Why?
|
Adenocarcinoma, Mucinous | 9 | 2019 | 31 | 0.980 |
Why?
|
Intestinal Fistula | 3 | 2020 | 10 | 0.880 |
Why?
|
Middle Aged | 89 | 2022 | 17391 | 0.850 |
Why?
|
Duodenal Diseases | 2 | 2020 | 15 | 0.840 |
Why?
|
Sphincter of Oddi Dysfunction | 3 | 2023 | 3 | 0.800 |
Why?
|
Pancreatic Diseases | 7 | 2015 | 39 | 0.800 |
Why?
|
Mesenteric Veins | 2 | 2020 | 11 | 0.790 |
Why?
|
Humans | 138 | 2023 | 62865 | 0.780 |
Why?
|
Pancreatitis | 6 | 2023 | 97 | 0.760 |
Why?
|
Female | 111 | 2022 | 32566 | 0.760 |
Why?
|
Gallbladder | 12 | 2007 | 37 | 0.720 |
Why?
|
Gallstones | 3 | 2020 | 25 | 0.710 |
Why?
|
Patient Discharge | 3 | 2023 | 505 | 0.710 |
Why?
|
Aged | 66 | 2022 | 14268 | 0.710 |
Why?
|
Male | 93 | 2022 | 29552 | 0.700 |
Why?
|
Nomograms | 1 | 2020 | 17 | 0.680 |
Why?
|
Pancreas | 7 | 2019 | 149 | 0.670 |
Why?
|
Vascular Fistula | 1 | 2020 | 8 | 0.670 |
Why?
|
Crohn Disease | 2 | 2020 | 111 | 0.660 |
Why?
|
Stomach Neoplasms | 1 | 2020 | 78 | 0.650 |
Why?
|
Patient Readmission | 7 | 2023 | 429 | 0.650 |
Why?
|
Adult | 60 | 2022 | 16672 | 0.630 |
Why?
|
Venous Thrombosis | 5 | 2022 | 114 | 0.620 |
Why?
|
Cholangiocarcinoma | 8 | 2012 | 30 | 0.590 |
Why?
|
Choledochostomy | 1 | 2018 | 3 | 0.580 |
Why?
|
Common Bile Duct | 1 | 2018 | 19 | 0.580 |
Why?
|
Duodenum | 1 | 2018 | 42 | 0.570 |
Why?
|
Pancreatic Cyst | 6 | 2018 | 24 | 0.570 |
Why?
|
Hepatectomy | 7 | 2022 | 63 | 0.570 |
Why?
|
Bile Duct Neoplasms | 7 | 2012 | 46 | 0.550 |
Why?
|
Treatment Outcome | 36 | 2023 | 5596 | 0.540 |
Why?
|
Carcinoma, Papillary | 6 | 2019 | 35 | 0.530 |
Why?
|
Incidence | 19 | 2022 | 1373 | 0.500 |
Why?
|
Aged, 80 and over | 31 | 2021 | 5408 | 0.470 |
Why?
|
Debridement | 5 | 2022 | 32 | 0.470 |
Why?
|
Palliative Care | 8 | 2017 | 226 | 0.460 |
Why?
|
Bile Ducts, Intrahepatic | 6 | 2010 | 26 | 0.460 |
Why?
|
Digestive System Surgical Procedures | 3 | 2023 | 91 | 0.450 |
Why?
|
Length of Stay | 15 | 2021 | 805 | 0.440 |
Why?
|
Gastroparesis | 3 | 2019 | 8 | 0.420 |
Why?
|
Obesity | 10 | 2022 | 1230 | 0.410 |
Why?
|
Gallbladder Diseases | 4 | 2007 | 25 | 0.410 |
Why?
|
Laparotomy | 3 | 2021 | 51 | 0.410 |
Why?
|
Risk Factors | 20 | 2023 | 5309 | 0.390 |
Why?
|
Survival Rate | 16 | 2020 | 843 | 0.380 |
Why?
|
Blood Loss, Surgical | 3 | 2018 | 62 | 0.350 |
Why?
|
Liver Diseases | 2 | 2022 | 148 | 0.350 |
Why?
|
Neoplasm Invasiveness | 12 | 2018 | 272 | 0.350 |
Why?
|
Indiana | 10 | 2021 | 21 | 0.340 |
Why?
|
Tomography, X-Ray Computed | 10 | 2020 | 1589 | 0.330 |
Why?
|
Bile | 6 | 2019 | 19 | 0.330 |
Why?
|
Clinical Competence | 3 | 2020 | 713 | 0.320 |
Why?
|
Surgical Wound Infection | 4 | 2023 | 114 | 0.320 |
Why?
|
Pancreaticojejunostomy | 3 | 2017 | 5 | 0.320 |
Why?
|
Sphincterotomy, Transduodenal | 3 | 2023 | 4 | 0.320 |
Why?
|
Leptin | 8 | 2006 | 85 | 0.320 |
Why?
|
Insulin Resistance | 3 | 2007 | 410 | 0.300 |
Why?
|
Colorectal Neoplasms | 2 | 2023 | 280 | 0.300 |
Why?
|
Cholelithiasis | 4 | 2004 | 23 | 0.300 |
Why?
|
Muscle, Smooth | 3 | 2019 | 134 | 0.290 |
Why?
|
Gastrostomy | 3 | 2019 | 29 | 0.290 |
Why?
|
Biliary Tract Surgical Procedures | 2 | 2010 | 12 | 0.290 |
Why?
|
Biliary Fistula | 2 | 2020 | 4 | 0.280 |
Why?
|
Prognosis | 12 | 2020 | 1727 | 0.280 |
Why?
|
Follow-Up Studies | 14 | 2020 | 2444 | 0.270 |
Why?
|
Cholangiopancreatography, Endoscopic Retrograde | 4 | 2023 | 46 | 0.270 |
Why?
|
Prospective Studies | 12 | 2023 | 3263 | 0.260 |
Why?
|
Splenic Artery | 2 | 2020 | 9 | 0.260 |
Why?
|
Postoperative Care | 3 | 2018 | 121 | 0.260 |
Why?
|
Preoperative Care | 7 | 2017 | 188 | 0.260 |
Why?
|
Gallbladder Neoplasms | 1 | 2006 | 16 | 0.260 |
Why?
|
Hernia, Ventral | 2 | 2020 | 25 | 0.250 |
Why?
|
Splenectomy | 2 | 2019 | 42 | 0.250 |
Why?
|
Gallbladder Emptying | 5 | 2006 | 5 | 0.250 |
Why?
|
Neuroendocrine Tumors | 2 | 2019 | 22 | 0.250 |
Why?
|
Necrosis | 6 | 2022 | 143 | 0.230 |
Why?
|
Logistic Models | 6 | 2020 | 1275 | 0.230 |
Why?
|
Intestinal Obstruction | 2 | 2020 | 53 | 0.230 |
Why?
|
Cholesterol | 8 | 2007 | 259 | 0.230 |
Why?
|
Aneurysm, False | 2 | 2020 | 50 | 0.220 |
Why?
|
Insulin | 3 | 2006 | 687 | 0.220 |
Why?
|
Negative-Pressure Wound Therapy | 1 | 2023 | 12 | 0.200 |
Why?
|
Surgical Wound | 1 | 2023 | 10 | 0.200 |
Why?
|
Biliary Tract Neoplasms | 1 | 2002 | 9 | 0.200 |
Why?
|
Cholangitis | 2 | 2019 | 11 | 0.200 |
Why?
|
Analgesia | 1 | 2022 | 31 | 0.200 |
Why?
|
Pancreatitis, Chronic | 3 | 2020 | 19 | 0.200 |
Why?
|
Pain, Postoperative | 3 | 2022 | 161 | 0.200 |
Why?
|
Dilatation, Pathologic | 2 | 2019 | 31 | 0.190 |
Why?
|
Neoplasm Staging | 7 | 2017 | 487 | 0.190 |
Why?
|
Young Adult | 11 | 2020 | 4655 | 0.190 |
Why?
|
Cystadenoma, Mucinous | 2 | 2017 | 5 | 0.190 |
Why?
|
Colonic Diseases | 1 | 2022 | 34 | 0.190 |
Why?
|
Hyperamylasemia | 1 | 2021 | 1 | 0.190 |
Why?
|
Cholangiopancreatography, Magnetic Resonance | 2 | 2014 | 10 | 0.180 |
Why?
|
Patient Selection | 7 | 2019 | 482 | 0.180 |
Why?
|
Disease Progression | 4 | 2022 | 1159 | 0.180 |
Why?
|
Hypertriglyceridemia | 1 | 2021 | 8 | 0.180 |
Why?
|
Adolescent | 10 | 2020 | 6195 | 0.180 |
Why?
|
Internship and Residency | 2 | 2020 | 788 | 0.170 |
Why?
|
Ursodeoxycholic Acid | 1 | 2020 | 7 | 0.170 |
Why?
|
Portal Vein | 2 | 2022 | 38 | 0.170 |
Why?
|
Surgical Mesh | 1 | 2020 | 61 | 0.170 |
Why?
|
Gastrectomy | 1 | 2020 | 40 | 0.170 |
Why?
|
Lung Diseases | 1 | 2022 | 175 | 0.170 |
Why?
|
Pulmonary Embolism | 2 | 2020 | 171 | 0.170 |
Why?
|
Wound Closure Techniques | 1 | 2020 | 7 | 0.170 |
Why?
|
Leukocytosis | 1 | 2019 | 13 | 0.160 |
Why?
|
Pancreatic Pseudocyst | 1 | 2019 | 12 | 0.160 |
Why?
|
Anti-Bacterial Agents | 4 | 2019 | 786 | 0.160 |
Why?
|
Amylases | 2 | 2021 | 12 | 0.160 |
Why?
|
Peritoneal Lavage | 1 | 2019 | 4 | 0.160 |
Why?
|
Sphincterotomy, Endoscopic | 2 | 2023 | 7 | 0.160 |
Why?
|
Emergencies | 1 | 2020 | 115 | 0.160 |
Why?
|
Survivors | 1 | 2020 | 170 | 0.160 |
Why?
|
Activins | 1 | 2019 | 54 | 0.160 |
Why?
|
Nurse's Role | 1 | 2020 | 120 | 0.160 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2020 | 79 | 0.160 |
Why?
|
Positron-Emission Tomography | 3 | 2015 | 208 | 0.160 |
Why?
|
Workload | 1 | 2019 | 121 | 0.160 |
Why?
|
Constriction, Pathologic | 4 | 2020 | 120 | 0.160 |
Why?
|
Lipase | 2 | 2021 | 50 | 0.150 |
Why?
|
Biliary Tract Diseases | 1 | 2019 | 16 | 0.150 |
Why?
|
Analgesia, Epidural | 1 | 2019 | 28 | 0.150 |
Why?
|
Stomach | 1 | 2019 | 86 | 0.150 |
Why?
|
Deoxycytidine | 2 | 2017 | 42 | 0.150 |
Why?
|
BRCA2 Protein | 1 | 2019 | 14 | 0.150 |
Why?
|
Cholecystokinin | 4 | 2006 | 9 | 0.150 |
Why?
|
Time Factors | 9 | 2019 | 3749 | 0.150 |
Why?
|
DNA Fingerprinting | 1 | 2018 | 8 | 0.150 |
Why?
|
Dietary Carbohydrates | 3 | 2007 | 61 | 0.150 |
Why?
|
Travel | 1 | 2018 | 42 | 0.150 |
Why?
|
Clostridium Infections | 1 | 2019 | 49 | 0.150 |
Why?
|
Alcohol-Related Disorders | 1 | 2019 | 38 | 0.150 |
Why?
|
Enteral Nutrition | 2 | 2019 | 54 | 0.150 |
Why?
|
Cholecystectomy | 3 | 2007 | 34 | 0.150 |
Why?
|
Practice Patterns, Physicians' | 3 | 2022 | 709 | 0.150 |
Why?
|
Cholestasis | 2 | 1996 | 59 | 0.150 |
Why?
|
BRCA1 Protein | 1 | 2019 | 58 | 0.150 |
Why?
|
Gastric Bypass | 1 | 2019 | 76 | 0.150 |
Why?
|
Survival Analysis | 6 | 2015 | 578 | 0.150 |
Why?
|
Choledocholithiasis | 1 | 2018 | 4 | 0.150 |
Why?
|
Surgeons | 1 | 2021 | 181 | 0.150 |
Why?
|
Thrombosis | 1 | 2020 | 199 | 0.140 |
Why?
|
Analgesics | 1 | 2019 | 103 | 0.140 |
Why?
|
Perioperative Care | 1 | 2019 | 85 | 0.140 |
Why?
|
Cross Infection | 1 | 2019 | 160 | 0.140 |
Why?
|
Gastric Mucosa | 1 | 2017 | 53 | 0.140 |
Why?
|
Ambulatory Care | 1 | 2020 | 311 | 0.140 |
Why?
|
Medical History Taking | 1 | 2017 | 67 | 0.140 |
Why?
|
Liver Neoplasms | 1 | 2020 | 295 | 0.140 |
Why?
|
Cholecystitis | 2 | 2007 | 29 | 0.140 |
Why?
|
Hepatic Duct, Common | 1 | 2017 | 7 | 0.140 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2020 | 337 | 0.140 |
Why?
|
Jejunum | 1 | 2017 | 14 | 0.140 |
Why?
|
Peripheral Nerves | 1 | 2017 | 34 | 0.140 |
Why?
|
Patient Care Team | 2 | 2017 | 337 | 0.140 |
Why?
|
Venous Thromboembolism | 1 | 2019 | 148 | 0.140 |
Why?
|
Cancer Pain | 1 | 2017 | 15 | 0.140 |
Why?
|
Abdominal Pain | 1 | 2018 | 101 | 0.140 |
Why?
|
Carcinoembryonic Antigen | 2 | 1999 | 32 | 0.140 |
Why?
|
Patient Safety | 1 | 2019 | 242 | 0.130 |
Why?
|
Anastomotic Leak | 1 | 2017 | 35 | 0.130 |
Why?
|
Liver Cirrhosis | 1 | 2018 | 171 | 0.130 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2017 | 42 | 0.130 |
Why?
|
Proton Pump Inhibitors | 2 | 2015 | 42 | 0.130 |
Why?
|
Embolization, Therapeutic | 1 | 2020 | 314 | 0.130 |
Why?
|
Radiotherapy | 1 | 2017 | 64 | 0.130 |
Why?
|
Chemoradiotherapy | 1 | 2017 | 65 | 0.130 |
Why?
|
Patient Education as Topic | 1 | 2020 | 462 | 0.130 |
Why?
|
Diagnosis, Differential | 6 | 2020 | 964 | 0.130 |
Why?
|
Blood Glucose | 7 | 2007 | 485 | 0.130 |
Why?
|
Sphincter of Oddi | 3 | 2019 | 4 | 0.120 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2015 | 31 | 0.120 |
Why?
|
Inpatients | 1 | 2018 | 302 | 0.120 |
Why?
|
Databases, Factual | 5 | 2018 | 853 | 0.120 |
Why?
|
Fellowships and Scholarships | 1 | 2017 | 104 | 0.120 |
Why?
|
Lipoma | 1 | 2015 | 18 | 0.120 |
Why?
|
Adenocarcinoma, Papillary | 1 | 2015 | 9 | 0.120 |
Why?
|
Gene Expression Profiling | 1 | 2019 | 769 | 0.120 |
Why?
|
Financing, Organized | 1 | 2015 | 16 | 0.120 |
Why?
|
Biomarkers, Tumor | 4 | 2014 | 503 | 0.120 |
Why?
|
Surgical Stapling | 1 | 2015 | 12 | 0.120 |
Why?
|
Anti-Ulcer Agents | 1 | 2015 | 9 | 0.120 |
Why?
|
CA-19-9 Antigen | 3 | 2014 | 10 | 0.120 |
Why?
|
Intubation, Gastrointestinal | 3 | 2021 | 21 | 0.120 |
Why?
|
Publications | 1 | 2015 | 29 | 0.120 |
Why?
|
Common Bile Duct Neoplasms | 1 | 1995 | 5 | 0.120 |
Why?
|
Peptic Ulcer | 1 | 2015 | 20 | 0.120 |
Why?
|
Splenic Vein | 1 | 2014 | 2 | 0.120 |
Why?
|
Ampulla of Vater | 1 | 1995 | 12 | 0.120 |
Why?
|
Hyperlipidemias | 2 | 2006 | 34 | 0.120 |
Why?
|
Lymph Node Excision | 2 | 2006 | 42 | 0.120 |
Why?
|
Cystadenoma, Serous | 2 | 2005 | 4 | 0.110 |
Why?
|
Adenoma | 1 | 2014 | 68 | 0.110 |
Why?
|
Liver Abscess, Pyogenic | 1 | 2014 | 1 | 0.110 |
Why?
|
Neoplasms, Cystic, Mucinous, and Serous | 1 | 2014 | 4 | 0.110 |
Why?
|
Lipids | 2 | 2007 | 316 | 0.110 |
Why?
|
Autoimmune Diseases | 1 | 2015 | 231 | 0.110 |
Why?
|
Parasympatholytics | 1 | 2013 | 7 | 0.110 |
Why?
|
Health Services Accessibility | 1 | 2018 | 554 | 0.110 |
Why?
|
Continuity of Patient Care | 1 | 2015 | 173 | 0.110 |
Why?
|
Antidepressive Agents, Tricyclic | 1 | 2013 | 19 | 0.110 |
Why?
|
Ultrasonography | 3 | 2020 | 475 | 0.110 |
Why?
|
Genetic Predisposition to Disease | 3 | 2023 | 716 | 0.100 |
Why?
|
Predictive Value of Tests | 5 | 2020 | 1078 | 0.100 |
Why?
|
Mutation | 2 | 2019 | 2598 | 0.100 |
Why?
|
Faculty, Medical | 1 | 2015 | 198 | 0.100 |
Why?
|
Precancerous Conditions | 1 | 2014 | 70 | 0.100 |
Why?
|
Catheter Ablation | 1 | 2015 | 153 | 0.100 |
Why?
|
Bile Ducts | 1 | 2012 | 25 | 0.100 |
Why?
|
Deep Sedation | 1 | 2012 | 4 | 0.100 |
Why?
|
Animals | 18 | 2019 | 20620 | 0.100 |
Why?
|
Body Weight | 7 | 2007 | 377 | 0.100 |
Why?
|
Body Mass Index | 3 | 2019 | 864 | 0.100 |
Why?
|
Disease-Free Survival | 4 | 2016 | 241 | 0.100 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 4 | 2022 | 446 | 0.090 |
Why?
|
Smoking | 1 | 2016 | 864 | 0.090 |
Why?
|
Natural Orifice Endoscopic Surgery | 1 | 2012 | 39 | 0.090 |
Why?
|
Mice, Inbred C57BL | 10 | 2007 | 3389 | 0.090 |
Why?
|
Nitric Oxide Synthase | 2 | 2001 | 47 | 0.090 |
Why?
|
Liver | 3 | 2012 | 846 | 0.090 |
Why?
|
Antineoplastic Agents | 1 | 2017 | 661 | 0.090 |
Why?
|
Anemia, Iron-Deficiency | 2 | 2001 | 22 | 0.090 |
Why?
|
Chi-Square Distribution | 4 | 2019 | 416 | 0.090 |
Why?
|
Neoadjuvant Therapy | 2 | 2022 | 82 | 0.090 |
Why?
|
Reoperation | 3 | 2019 | 290 | 0.090 |
Why?
|
Crystallization | 6 | 2007 | 99 | 0.090 |
Why?
|
Anastomosis, Surgical | 3 | 2020 | 111 | 0.080 |
Why?
|
Mice | 13 | 2019 | 10819 | 0.080 |
Why?
|
Sensitivity and Specificity | 3 | 2018 | 1140 | 0.080 |
Why?
|
Treatment Failure | 2 | 2020 | 199 | 0.080 |
Why?
|
Robotics | 1 | 2010 | 77 | 0.080 |
Why?
|
Dietary Fats | 2 | 2007 | 176 | 0.080 |
Why?
|
Social Class | 1 | 2010 | 133 | 0.080 |
Why?
|
Endosonography | 3 | 2017 | 26 | 0.080 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 2 | 2019 | 18 | 0.080 |
Why?
|
Bile Ducts, Extrahepatic | 2 | 2006 | 3 | 0.070 |
Why?
|
Combined Modality Therapy | 3 | 2017 | 369 | 0.070 |
Why?
|
Operative Time | 2 | 2019 | 91 | 0.070 |
Why?
|
Lipid Metabolism | 2 | 2007 | 220 | 0.070 |
Why?
|
Cholesterol, Dietary | 2 | 2006 | 29 | 0.070 |
Why?
|
Adipose Tissue | 2 | 2007 | 296 | 0.070 |
Why?
|
Cholangitis, Sclerosing | 2 | 1999 | 13 | 0.070 |
Why?
|
Dinoprostone | 1 | 2007 | 43 | 0.070 |
Why?
|
Risk Assessment | 5 | 2019 | 2051 | 0.070 |
Why?
|
Proportional Hazards Models | 3 | 2019 | 729 | 0.070 |
Why?
|
Azetidines | 1 | 2007 | 8 | 0.070 |
Why?
|
Morbidity | 2 | 2020 | 113 | 0.070 |
Why?
|
Anticholesteremic Agents | 1 | 2007 | 35 | 0.070 |
Why?
|
Statistics, Nonparametric | 4 | 2009 | 213 | 0.070 |
Why?
|
Gastric Outlet Obstruction | 1 | 2007 | 2 | 0.070 |
Why?
|
Resistin | 1 | 2007 | 6 | 0.070 |
Why?
|
Pain Measurement | 2 | 2019 | 343 | 0.070 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2007 | 33 | 0.070 |
Why?
|
Fibroblasts | 2 | 2019 | 392 | 0.070 |
Why?
|
Midwestern United States | 1 | 2006 | 25 | 0.070 |
Why?
|
Multivariate Analysis | 2 | 2014 | 934 | 0.060 |
Why?
|
Thiazolidinediones | 1 | 2006 | 50 | 0.060 |
Why?
|
Healthcare Disparities | 1 | 2010 | 352 | 0.060 |
Why?
|
Hospital Mortality | 2 | 2021 | 867 | 0.060 |
Why?
|
Biopsy, Fine-Needle | 2 | 2018 | 63 | 0.060 |
Why?
|
Gene Expression | 2 | 2019 | 838 | 0.060 |
Why?
|
Radiography, Abdominal | 1 | 2005 | 26 | 0.060 |
Why?
|
Mice, Obese | 4 | 2006 | 80 | 0.060 |
Why?
|
United States | 4 | 2020 | 7744 | 0.060 |
Why?
|
Dissection | 1 | 2005 | 48 | 0.060 |
Why?
|
Early Detection of Cancer | 2 | 2023 | 315 | 0.060 |
Why?
|
Case-Control Studies | 2 | 2021 | 1115 | 0.060 |
Why?
|
Cystadenoma | 1 | 2004 | 6 | 0.060 |
Why?
|
Intestine, Small | 1 | 2005 | 79 | 0.060 |
Why?
|
Hypoglycemic Agents | 1 | 2006 | 214 | 0.060 |
Why?
|
Pylorus | 1 | 2004 | 10 | 0.060 |
Why?
|
Magnetic Resonance Imaging | 4 | 2019 | 2150 | 0.060 |
Why?
|
Acetylcholine | 4 | 2006 | 44 | 0.050 |
Why?
|
Myocytes, Smooth Muscle | 1 | 2004 | 60 | 0.050 |
Why?
|
Adenoma, Islet Cell | 1 | 2003 | 4 | 0.050 |
Why?
|
Cohort Studies | 4 | 2011 | 2549 | 0.050 |
Why?
|
Preoperative Period | 2 | 2017 | 69 | 0.050 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2017 | 85 | 0.050 |
Why?
|
Recurrence | 3 | 2014 | 636 | 0.050 |
Why?
|
Mice, Inbred NOD | 1 | 2004 | 521 | 0.050 |
Why?
|
Severity of Illness Index | 2 | 2022 | 1541 | 0.050 |
Why?
|
Carcinoma | 1 | 2004 | 125 | 0.050 |
Why?
|
Germ-Line Mutation | 1 | 2023 | 45 | 0.050 |
Why?
|
Stents | 1 | 2007 | 487 | 0.050 |
Why?
|
Muscle Contraction | 2 | 2019 | 202 | 0.050 |
Why?
|
Diet | 1 | 2006 | 523 | 0.050 |
Why?
|
Diabetes Mellitus | 2 | 2004 | 536 | 0.050 |
Why?
|
Acute Disease | 1 | 2023 | 671 | 0.050 |
Why?
|
Ileum | 1 | 2001 | 22 | 0.050 |
Why?
|
Biomarkers | 2 | 2019 | 1388 | 0.050 |
Why?
|
Decompression | 1 | 2021 | 1 | 0.050 |
Why?
|
Gastric Emptying | 1 | 2021 | 6 | 0.050 |
Why?
|
Organ Size | 3 | 2007 | 171 | 0.050 |
Why?
|
North America | 2 | 2012 | 111 | 0.050 |
Why?
|
Gastric Fistula | 1 | 2020 | 4 | 0.040 |
Why?
|
Exocrine Pancreatic Insufficiency | 1 | 2020 | 7 | 0.040 |
Why?
|
Splanchnic Circulation | 1 | 2020 | 16 | 0.040 |
Why?
|
Propensity Score | 1 | 2021 | 154 | 0.040 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2020 | 25 | 0.040 |
Why?
|
Factor Xa Inhibitors | 1 | 2020 | 35 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 2 | 2012 | 418 | 0.040 |
Why?
|
Carcinoma, Renal Cell | 1 | 2001 | 93 | 0.040 |
Why?
|
Immunohistochemistry | 2 | 2019 | 890 | 0.040 |
Why?
|
Genotype | 1 | 2002 | 666 | 0.040 |
Why?
|
Herniorrhaphy | 1 | 2020 | 69 | 0.040 |
Why?
|
Health Plan Implementation | 1 | 2020 | 40 | 0.040 |
Why?
|
Triglycerides | 3 | 2007 | 244 | 0.040 |
Why?
|
Retreatment | 1 | 2020 | 47 | 0.040 |
Why?
|
Leukocyte Count | 1 | 2019 | 96 | 0.040 |
Why?
|
Odds Ratio | 1 | 2022 | 769 | 0.040 |
Why?
|
Kidney Neoplasms | 1 | 2001 | 145 | 0.040 |
Why?
|
Efficiency | 1 | 2019 | 39 | 0.040 |
Why?
|
Cachexia | 1 | 2019 | 9 | 0.040 |
Why?
|
Activin Receptors, Type II | 1 | 2019 | 9 | 0.040 |
Why?
|
Heparin | 1 | 2020 | 116 | 0.040 |
Why?
|
Colectomy | 1 | 2020 | 108 | 0.040 |
Why?
|
Body Weights and Measures | 1 | 2019 | 33 | 0.040 |
Why?
|
Syndrome | 1 | 2019 | 179 | 0.040 |
Why?
|
Actuarial Analysis | 2 | 1999 | 17 | 0.040 |
Why?
|
Intraoperative Care | 1 | 2019 | 38 | 0.040 |
Why?
|
Lymphoma | 1 | 2000 | 101 | 0.040 |
Why?
|
Muscular Atrophy | 1 | 2019 | 26 | 0.040 |
Why?
|
Failure to Thrive | 1 | 2019 | 8 | 0.040 |
Why?
|
Centralized Hospital Services | 1 | 2018 | 6 | 0.040 |
Why?
|
Fatigue | 1 | 2019 | 112 | 0.040 |
Why?
|
Genes, ras | 1 | 1998 | 27 | 0.040 |
Why?
|
Nurses | 1 | 2020 | 104 | 0.040 |
Why?
|
Reference Values | 1 | 2019 | 335 | 0.040 |
Why?
|
Genes, p53 | 1 | 1998 | 52 | 0.040 |
Why?
|
Hospitals, High-Volume | 1 | 2018 | 32 | 0.040 |
Why?
|
Islets of Langerhans | 1 | 2020 | 279 | 0.040 |
Why?
|
Muscle Fibers, Skeletal | 1 | 2019 | 93 | 0.040 |
Why?
|
Renal Insufficiency | 1 | 2019 | 67 | 0.040 |
Why?
|
Quality of Life | 2 | 2023 | 1221 | 0.040 |
Why?
|
Heterozygote | 1 | 2019 | 168 | 0.040 |
Why?
|
Age Factors | 2 | 2016 | 1556 | 0.040 |
Why?
|
Anticoagulants | 1 | 2022 | 495 | 0.040 |
Why?
|
Progesterone | 1 | 1999 | 163 | 0.040 |
Why?
|
Interstitial Cells of Cajal | 1 | 2017 | 2 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-sis | 1 | 2017 | 5 | 0.040 |
Why?
|
Chronic Pain | 1 | 2020 | 150 | 0.040 |
Why?
|
Genetic Testing | 1 | 2019 | 131 | 0.040 |
Why?
|
Heme Oxygenase-1 | 1 | 2017 | 20 | 0.040 |
Why?
|
Stem Cell Factor | 1 | 2017 | 26 | 0.040 |
Why?
|
Program Evaluation | 1 | 2020 | 486 | 0.040 |
Why?
|
Neoplasm Grading | 1 | 2017 | 86 | 0.040 |
Why?
|
Anoctamin-1 | 1 | 2017 | 16 | 0.040 |
Why?
|
Clinical Decision-Making | 1 | 2019 | 160 | 0.040 |
Why?
|
Obesity, Morbid | 1 | 2019 | 97 | 0.030 |
Why?
|
Conversion to Open Surgery | 1 | 2017 | 9 | 0.030 |
Why?
|
Disease Management | 1 | 2019 | 234 | 0.030 |
Why?
|
Double-Blind Method | 1 | 2019 | 739 | 0.030 |
Why?
|
Analgesics, Opioid | 1 | 2022 | 532 | 0.030 |
Why?
|
Failure to Rescue, Health Care | 1 | 2017 | 5 | 0.030 |
Why?
|
Endoscopy | 1 | 2017 | 109 | 0.030 |
Why?
|
Disease Models, Animal | 2 | 2019 | 2179 | 0.030 |
Why?
|
Random Allocation | 2 | 2012 | 198 | 0.030 |
Why?
|
Fatty Acids, Nonesterified | 2 | 2007 | 56 | 0.030 |
Why?
|
Phospholipids | 2 | 2007 | 81 | 0.030 |
Why?
|
Choledochal Cyst | 1 | 1996 | 3 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2007 | 455 | 0.030 |
Why?
|
Universities | 1 | 2017 | 157 | 0.030 |
Why?
|
Neoplasm Proteins | 1 | 2017 | 283 | 0.030 |
Why?
|
Dogs | 2 | 2012 | 325 | 0.030 |
Why?
|
Surgery Department, Hospital | 1 | 2015 | 21 | 0.030 |
Why?
|
Quality of Health Care | 1 | 2019 | 517 | 0.030 |
Why?
|
Kidney Diseases | 1 | 2017 | 174 | 0.030 |
Why?
|
Neuropeptide Y | 2 | 2006 | 13 | 0.030 |
Why?
|
Jejunostomy | 2 | 2010 | 7 | 0.030 |
Why?
|
Cell Line, Tumor | 1 | 2019 | 1455 | 0.030 |
Why?
|
Histamine H2 Antagonists | 1 | 2015 | 15 | 0.030 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2015 | 116 | 0.030 |
Why?
|
Alkaline Phosphatase | 1 | 2014 | 46 | 0.030 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2010 | 59 | 0.030 |
Why?
|
Early Termination of Clinical Trials | 1 | 2014 | 5 | 0.030 |
Why?
|
Hospitalization | 1 | 2022 | 1346 | 0.030 |
Why?
|
False Negative Reactions | 1 | 2014 | 40 | 0.030 |
Why?
|
Early Diagnosis | 1 | 2014 | 96 | 0.030 |
Why?
|
Neurotransmitter Agents | 2 | 2004 | 42 | 0.030 |
Why?
|
False Positive Reactions | 1 | 2014 | 78 | 0.030 |
Why?
|
Drug Resistance | 2 | 2004 | 152 | 0.030 |
Why?
|
Quality Improvement | 1 | 2017 | 439 | 0.020 |
Why?
|
Peptide Fragments | 2 | 2006 | 411 | 0.020 |
Why?
|
Decision Support Techniques | 1 | 2014 | 194 | 0.020 |
Why?
|
Sciuridae | 2 | 2001 | 3 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2007 | 1640 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2017 | 1534 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 1995 | 730 | 0.020 |
Why?
|
Ligation | 1 | 2011 | 38 | 0.020 |
Why?
|
Heart Failure | 1 | 2019 | 901 | 0.020 |
Why?
|
Practice Guidelines as Topic | 1 | 2015 | 727 | 0.020 |
Why?
|
Health Care Costs | 1 | 2012 | 209 | 0.020 |
Why?
|
Algorithms | 2 | 2010 | 1003 | 0.020 |
Why?
|
Minimally Invasive Surgical Procedures | 1 | 2011 | 122 | 0.020 |
Why?
|
Down-Regulation | 2 | 2001 | 318 | 0.020 |
Why?
|
Fluorouracil | 1 | 2010 | 66 | 0.020 |
Why?
|
Florida | 1 | 2010 | 48 | 0.020 |
Why?
|
Blotting, Western | 2 | 2001 | 610 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2012 | 562 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2011 | 608 | 0.020 |
Why?
|
Contraindications | 1 | 2009 | 49 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2011 | 317 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2010 | 309 | 0.020 |
Why?
|
Signal Transduction | 1 | 2019 | 3027 | 0.020 |
Why?
|
Postoperative Period | 1 | 2009 | 138 | 0.020 |
Why?
|
Ezetimibe | 1 | 2007 | 6 | 0.020 |
Why?
|
Cholesterol Esters | 1 | 2007 | 10 | 0.020 |
Why?
|
Poverty | 1 | 2010 | 295 | 0.020 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2007 | 71 | 0.020 |
Why?
|
Viscera | 1 | 2007 | 10 | 0.020 |
Why?
|
Sodium | 1 | 2007 | 62 | 0.020 |
Why?
|
Osmolar Concentration | 1 | 2007 | 89 | 0.020 |
Why?
|
Cholinergic Agents | 1 | 2006 | 9 | 0.020 |
Why?
|
Decision Making | 1 | 2010 | 402 | 0.020 |
Why?
|
Angiography | 1 | 2007 | 151 | 0.020 |
Why?
|
Comorbidity | 1 | 2010 | 1119 | 0.020 |
Why?
|
Butter | 1 | 2006 | 1 | 0.020 |
Why?
|
Radiography, Interventional | 1 | 2007 | 74 | 0.020 |
Why?
|
Mice, Inbred Strains | 1 | 2006 | 189 | 0.020 |
Why?
|
Barium Sulfate | 1 | 2005 | 18 | 0.010 |
Why?
|
Enema | 1 | 2005 | 14 | 0.010 |
Why?
|
Mice, Mutant Strains | 1 | 2004 | 302 | 0.010 |
Why?
|
Spleen | 1 | 2005 | 482 | 0.010 |
Why?
|
Vacuoles | 1 | 2003 | 26 | 0.010 |
Why?
|
Phenotype | 1 | 2007 | 1197 | 0.010 |
Why?
|
Cytokines | 1 | 2007 | 934 | 0.010 |
Why?
|
Diabetes Complications | 1 | 2003 | 106 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2004 | 863 | 0.010 |
Why?
|
Contrast Media | 1 | 2005 | 421 | 0.010 |
Why?
|
Receptors, Vasoactive Intestinal Peptide | 1 | 2001 | 1 | 0.010 |
Why?
|
Nitroarginine | 1 | 2001 | 2 | 0.010 |
Why?
|
Vasoactive Intestinal Peptide | 1 | 2001 | 17 | 0.010 |
Why?
|
Nitric Oxide Synthase Type I | 1 | 2001 | 7 | 0.010 |
Why?
|
Iron, Dietary | 1 | 2001 | 9 | 0.010 |
Why?
|
Electric Stimulation | 1 | 2001 | 140 | 0.010 |
Why?
|
Cytodiagnosis | 1 | 2001 | 46 | 0.010 |
Why?
|
Hemoglobins | 1 | 2001 | 135 | 0.010 |
Why?
|
Vincristine | 1 | 2000 | 27 | 0.010 |
Why?
|
Cyclophosphamide | 1 | 2000 | 79 | 0.010 |
Why?
|
Prednisone | 1 | 2000 | 86 | 0.010 |
Why?
|
Doxorubicin | 1 | 2000 | 99 | 0.010 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2000 | 68 | 0.010 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2004 | 620 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2001 | 373 | 0.010 |
Why?
|
West Virginia | 1 | 1998 | 6 | 0.010 |
Why?
|
Cause of Death | 1 | 1999 | 222 | 0.010 |
Why?
|
Linear Models | 1 | 1999 | 409 | 0.010 |
Why?
|
Inflammatory Bowel Diseases | 1 | 1999 | 101 | 0.010 |
Why?
|
Liver Transplantation | 1 | 1999 | 215 | 0.010 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 1998 | 303 | 0.010 |
Why?
|
Diagnostic Imaging | 1 | 1999 | 262 | 0.010 |
Why?
|
Child | 1 | 1999 | 4477 | 0.000 |
Why?
|